AVB-114

Phase 2Biologic

AAvobis Bio, LLC

AVB-114 is one of 9 biologic programs targeting Anal fistula. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anal FistulaActive, not recruiting

Anal FistulaPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Anal Fistula

#DrugCompanyPhaseTrials

Humira

Novartis

Approved

2 2

Acanya

Marcaine

Dilantin

VViatris Specialty LLC

Preclinical

—5

Amoxil

GGlobal Antibiotics Research and Development Partnership

AVB-114

1 7

E-CEL UVEC

WWeill Medical College of Cornell University

Phase 1

1 8

Amoxicillin-Clavulanate

IIterum Therapeutics, International Limited

Preclinical

1 9

Fibrin Glue

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection

Available·AAvobis Bio, LLC··NCT06509828

Anal fistula1 trial

Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

Active, not recruiting·AAvobis Bio, LLC·Phase 2·NCT04847739·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AVB-114. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AVB-114 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AVB-114. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avobis Bio, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAvobis Bio, LLC

AVB-114

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Anal fistula1 trial

References

Drug Info

Quick Facts

Related News